India on Saturday became the first country in the world to administer DNA vaccine against COVID-19.

It comes as India recorded a reduction of 1,03,921 cases in the active COVID-19 caseload in a span of 24 hours.

The national COVID-19 recovery rate has improved to 95.64 per cent, according to Union health ministry data.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
Bihar | Painless and Needleless ZYCOV-D Covid Vaccine launched in Patna 
 
Three doses will be given at intervals of 28 days and 56 days. This program has been started at 3 vaccination centers. It is good for people who are afraid of needles: Civil surgeon Dr Vibha Singh (04.03) <a href="https://t.co/bJ9JlidrZh">pic.twitter.com/bJ9JlidrZh</a>
— ANI (@ANI) <a href="https://twitter.com/ANI/status/1489749482002468865?ref_src=twsrc%5Etfw">February 4, 2022</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

The Indian government approved emergency use authorisation for Zydus Cadila's DNA vaccine earlier this year, citing initial results from Phase III clinical trials that showed approximately 66 percent efficacy for symptomatic cases.

The ZyCoV-D,&nbsp;the world's first plasmid DNA vaccine,&nbsp;was produced by Ahmedabad-based vaccine manufacturer Zydus Cadila.

Also read |&nbsp;<a href="https://www.wionews.com/trending/vitamin-d-deficiency-increases-covid-19-severity-study-450651" hreflang="en">Vitamin D deficiency increases COVID-19 severity: Study</a>

The Drugs Controller General of India has given its permission for the vaccination to be given to children aged 12 to 17.

Unlike most COVID-19 vaccines, which need two doses or even a single dose, ZyCoV-D is administered in three doses with a gap of 28 and 56 days from the first dose respectively.

Zydus Cadila's vaccine, developed in partnership with the Department of Biotechnology, is the second home-grown shot to get emergency authorisation in India after Bharat Biotech's Covaxin.

According to health ministry officials, over 93 per cent of the adult population have received at least one dose while over 69.8 per cent have been fully vaccinated.

"As a result of the country's solidarity and Prime Minister Narendra Modi ji's commitment during the Corona crisis that the country not only manufactured a vaccine but also inoculated a large part of the population in a very short time. This one year of vaccination campaign shows India's resolve," said Union Health Minister Mansukh Mandaviya.

With health workers going door-to-door to administer shots, Indian officials are carrying out a vaccination drive in remote parts of the country.

(With inputs from agencies)&nbsp;

India on Saturday became the first country in the world to administer DNA vaccine against COVID-19. It comes as India recorded a reduction of 1,03,921 cases in the active COVID-19 caseload in a span of 24 hours.

India on Saturday became the first country in the world to administer DNA vaccine against COVID-19. It comes as India recorded a reduction of 1,03,921 cases in the active COVID-19 caseload in a span of 24 hours. The national COVID-19 recovery rate has improved to 95.64 per cent, according to Union health ministry data. Bihar | Painless and Needleless ZYCOV-D Covid Vaccine launched in Patna Three doses will be given at intervals of 28 days and 56 days. This program has been started at 3 vaccination centers. It is good for people who are afraid of needles: Civil surgeon Dr Vibha Singh (04.03) pic.twitter.com/bJ9JlidrZh — ANI (@ANI) February 4, 2022 × The Indian government approved emergency use authorisation for Zydus Cadila's DNA vaccine earlier this year, citing initial results from Phase III clinical trials that showed approximately 66 percent efficacy for symptomatic cases. The ZyCoV-D, the world's first plasmid DNA vaccine, was produced by Ahmedabad-based vaccine manufacturer Zydus Cadila. Also read | Vitamin D deficiency increases COVID-19 severity: Study The Drugs Controller General of India has given its permission for the vaccination to be given to children aged 12 to 17. Unlike most COVID-19 vaccines, which need two doses or even a single dose, ZyCoV-D is administered in three doses with a gap of 28 and 56 days from the first dose respectively. Zydus Cadila's vaccine, developed in partnership with the Department of Biotechnology, is the second home-grown shot to get emergency authorisation in India after Bharat Biotech's Covaxin. According to health ministry officials, over 93 per cent of the adult population have received at least one dose while over 69.8 per cent have been fully vaccinated. "As a result of the country's solidarity and Prime Minister Narendra Modi ji's commitment during the Corona crisis that the country not only manufactured a vaccine but also inoculated a large part of the population in a very short time. This one year of vaccination campaign shows India's resolve," said Union Health Minister Mansukh Mandaviya. With health workers going door-to-door to administer shots, Indian officials are carrying out a vaccination drive in remote parts of the country. (With inputs from agencies)

India becomes first country in world to administer COVID-19 DNA vaccine

As the Omicron variant has rapidly reached nearly every corner of the Earth, Indian Prime Minister Narendra Modi on December 25, announced that the nasal vaccination and the world's first DNA vaccine against COVID-19 will be available for inoculation soon.

"Nasal vaccine and the world's first DNA vaccine against COVID-19 will soon commence in India," Prime Minister Narendra Modi stated in a speech to the country.

PM Modi also reassured Indians that the world's first DNA vaccine against COVID-19 is still being studied and produced.&nbsp;

The Indian government approved emergency use authorisation for Zydus Cadila's DNA vaccine earlier this year, citing initial results from Phase III clinical trials that showed approximately 66 percent efficacy for symptomatic cases.

The world's first DNA vaccine against the COVID-19

The ZyCoV-D – the world's first plasmid DNA vaccine – was produced by Ahmedabad-based vaccine manufacturer Zydus Cadila and got Emergency Use Approval (EUA) from the Drugs Controller General of India in August earlier this year.&nbsp;

The DCGI has given its permission for the vaccination to be given to children aged 12 to 17.

What is a DNA-based vaccine, and how does it work?

In its most basic form, DNA stores the memories of all biological activities, without exception. It also contains hereditary or genetic information about how the body should react in the event of infection. 
 
The DNA-based vaccinations operate by transferring a genetically modified blueprint of viral genes into small DNA molecules for injection into persons being vaccinated, according to the Milken Institute in the United States.

The ZyCoV-D was created by inserting a fragment of virus DNA into the human body, which, once inside, causes the virus to manufacture a crucial component that the immune system can recognise and so encounter. 
 
<a href="https://www.wionews.com/science/coronavirus-alpha-variant-has-learnt-how-to-evade-innate-immune-system-research-440242">Also read | Coronavirus' Alpha variant has learnt how to evade innate immune system: Research</a>

Painless vaccine delivery

Instead of using regular syringes, the world's first DNA vaccination will be administered using a needle-free applicator called "PharmaJet." The use of a needle-free applicator enables pain-free intradermal vaccine delivery, as well as a significant reduction in any major side effects.

Efficacy rate of the DNA vaccine

In clinical trials, the vaccination was proven to be 67 per cent effective against symptomatic COVID-19.

It demonstrates that DNA vaccinations work and can aid in the control of the pandemic.

At least a dozen DNA vaccines against COVID-19 are currently in clinical trials around the world, with at least as many more in the early phases of development. Vaccines based on DNA are also being developed for a variety of other disorders. 
 
Also read |&nbsp;<a href="https://www.wionews.com/world/pfizers-pill-against-covid-can-be-dangerous-when-taken-with-other-medications-440230">Pfizer's pill against Covid can be dangerous when taken with other medications</a> 
 
Safety

ZyCoV-D was found to be safe, well tolerated and immunogenic in the Adaptive Phase I/II clinical trials.

According to a statement by India's Ministry of Science &amp; Technology, this vaccine had already exhibited robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials carried out earlier.&nbsp;

Both the Phase I/II and Phase III clinical trials have been monitored by an independent Data Safety Monitoring Board (DSMB). 
 
Price 
 
Zydus Cadila has obtained an order from the Government of India to supply one crore doses of ZyCoV-D at a cost of $3.53 each dose, with the needle-free applicator costing $1.24 per dose, excluding GST. 
 
According to the price breakdown, the Centre will be able to purchase a single dose of the vaccine for $5, which includes the cost of the jet applicator and GST, bringing the total cost of the 3-dose shot to $15. 
 
(With inputs from agencies)

As the Omicron variant has rapidly reached nearly every corner of the Earth, Indian Prime Minister Narendra Modi on December 25, announced that the nasal vaccination and the world's first DNA vaccine against COVID-19 will be available for inoculation soon.

As the Omicron variant has rapidly reached nearly every corner of the Earth, Indian Prime Minister Narendra Modi on December 25, announced that the nasal vaccination and the world's first DNA vaccine against COVID-19 will be available for inoculation soon. "Nasal vaccine and the world's first DNA vaccine against COVID-19 will soon commence in India," Prime Minister Narendra Modi stated in a speech to the country. PM Modi also reassured Indians that the world's first DNA vaccine against COVID-19 is still being studied and produced. The Indian government approved emergency use authorisation for Zydus Cadila's DNA vaccine earlier this year, citing initial results from Phase III clinical trials that showed approximately 66 percent efficacy for symptomatic cases. The world's first DNA vaccine against the COVID-19 The ZyCoV-D – the world's first plasmid DNA vaccine – was produced by Ahmedabad-based vaccine manufacturer Zydus Cadila and got Emergency Use Approval (EUA) from the Drugs Controller General of India in August earlier this year. The DCGI has given its permission for the vaccination to be given to children aged 12 to 17. What is a DNA-based vaccine, and how does it work? In its most basic form, DNA stores the memories of all biological activities, without exception. It also contains hereditary or genetic information about how the body should react in the event of infection. The DNA-based vaccinations operate by transferring a genetically modified blueprint of viral genes into small DNA molecules for injection into persons being vaccinated, according to the Milken Institute in the United States. The ZyCoV-D was created by inserting a fragment of virus DNA into the human body, which, once inside, causes the virus to manufacture a crucial component that the immune system can recognise and so encounter. Also read | Coronavirus' Alpha variant has learnt how to evade innate immune system: Research Painless vaccine delivery Instead of using regular syringes, the world's first DNA vaccination will be administered using a needle-free applicator called "PharmaJet." The use of a needle-free applicator enables pain-free intradermal vaccine delivery, as well as a significant reduction in any major side effects. Efficacy rate of the DNA vaccine In clinical trials, the vaccination was proven to be 67 per cent effective against symptomatic COVID-19. It demonstrates that DNA vaccinations work and can aid in the control of the pandemic. At least a dozen DNA vaccines against COVID-19 are currently in clinical trials around the world, with at least as many more in the early phases of development. Vaccines based on DNA are also being developed for a variety of other disorders. Also read | Pfizer's pill against Covid can be dangerous when taken with other medications Safety ZyCoV-D was found to be safe, well tolerated and immunogenic in the Adaptive Phase I/II clinical trials. According to a statement by India's Ministry of Science & Technology, this vaccine had already exhibited robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials carried out earlier. Both the Phase I/II and Phase III clinical trials have been monitored by an independent Data Safety Monitoring Board (DSMB). Price Zydus Cadila has obtained an order from the Government of India to supply one crore doses of ZyCoV-D at a cost of $3.53 each dose, with the needle-free applicator costing $1.24 per dose, excluding GST. According to the price breakdown, the Centre will be able to purchase a single dose of the vaccine for $5, which includes the cost of the jet applicator and GST, bringing the total cost of the 3-dose shot to $15. (With inputs from agencies)

World's first DNA Covid vaccine from India: Cost, features, other details here

India has become the first country to approve the world's first DNA shot against the coronavirus. India's drug regulator has granted emergency use approval for Zydus Cadila's COVID-19 vaccine for adults and children aged 12 years and above. It is the second homegrown covid-19 vaccine for India. Also the first approved covid-19 vaccine for children older than 12 in the country.

Big boost to India's vaccination programme, vaccine approved for over 12-year-olds

zycov-d

Zycov D, News on Zycov D, stories on Zycov D, articles on Zycov D, Zycov D stories at Wion, Zycov D news, Zycov D latest news

zycov d

India becomes first country in world to administer COVID-19 DNA vaccine

World's first DNA Covid vaccine from India: Cost, features, other details here

Big boost to India's vaccination programme, vaccine approved for over 12-year-olds